Powder: -20°C for 3 years | In solvent: -80°C for 1 year
A-485 是 p300/CBP 的一种选择性催化抑制剂,对 p300和 CBP 组蛋白乙酰转移酶的 IC50值分别为 9.8 和 2.6 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 888 | 现货 | ||
2 mg | ¥ 1,330 | 现货 | ||
5 mg | ¥ 2,520 | 现货 | ||
10 mg | ¥ 3,710 | 现货 | ||
25 mg | ¥ 5,980 | 现货 | ||
50 mg | ¥ 8,190 | 现货 | ||
100 mg | ¥ 10,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,580 | 现货 |
产品描述 | A-485 is a potent and selective catalytic p300/CBP inhibitor(IC50s of 9.8 nM and 2.6 nM for p300 and CBP, respectively). |
靶点活性 | p300:9.8 nM, CBP:2.6 nM |
体外活性 | A three-hour treatment of prostate adenocarcinoma PC-3 cells with A-485 results in a dose-dependent decrease in H3K27Ac, with a half maximal effective concentration (EC50) of 73 nM. The broadest sensitivity is observed in haematological tumours, where A-485 exhibits potent activity in most multiple myeloma cell lines, and in a subset of acute myeloid leukaemia lines and non-Hodgkin’s lymphoma lines. Treatment with A-485 does not alter p300 or CBP protein levels, but it induces a comparable decrease in H3K27Ac in all five prostate cancer cell lines[1]. |
体内活性 | A-485, a potent, selective and drug-like catalytic inhibitor of p300 and CBP.?A-485 selectively inhibited proliferation in lineage-specific tumour types, including several haematological malignancies and androgen receptor-positive prostate cancer.?A-485 inhibited the androgen receptor transcriptional program in both androgen-sensitive and castration-resistant prostate cancer and inhibited tumour growth in a castration-resistant xenograft model.?After tumours are established in SCID male mice, twice daily intraperitoneal injections of A-485 induce 54% tumour growth inhibition after 21 days of dosing (P<0.005 as compare to vehicle control).?A-485 induces a moderate 9% body weight loss, and the animals recover rapidly upon completion of the A-485 dosing regimen[1].?In tumour-bearing animals, dosing with A-485 for seven days induces a decrease in the mRNA levels of MYC and the AR-dependent gene SLC45A3 at three hours post-dosing, and (for MYC) a decrease in the protein level, indicating that A-485 inhibits p300-mediated transcriptional activity in vivo.?But, at 16?hours post-dosing on the seventh day, A-485 drug levels in the plasma and tumour are decreased as compare to 3?hours. |
分子量 | 536.48 |
分子式 | C25H24F4N4O5 |
CAS No. | 1889279-16-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (186.40 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.864 mL | 9.32 mL | 18.64 mL | 46.6001 mL |
5 mM | 0.3728 mL | 1.864 mL | 3.728 mL | 9.32 mL | |
10 mM | 0.1864 mL | 0.932 mL | 1.864 mL | 4.66 mL | |
20 mM | 0.0932 mL | 0.466 mL | 0.932 mL | 2.33 mL | |
50 mM | 0.0373 mL | 0.1864 mL | 0.3728 mL | 0.932 mL | |
100 mM | 0.0186 mL | 0.0932 mL | 0.1864 mL | 0.466 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
A-485 1889279-16-6 Chromatin/Epigenetic Epigenetic Reader Domain Histone Acetyltransferase inhibit HATs Inhibitor A485 HAT A 485 inhibitor